ORGENTEC Diagnostika GmbH

Carl-Zeiss-Straße 49-51 55129 Mainz - Germany

Phone: +49 (0) 61 31 / 92 58-0 Fax: +49 (0) 61 31 / 92 58-58

Internet: www.orgentec.com



www.orgentec.com







REF ORG 540A Anti-Tissue-Transglutaminase IgA

INTENDED PURPOSE

Anti-Tissue-Transglutaminase IgA is an ELISA test system for the quantitative measurement of IgA class autoantibodies to tissue transglutaminase (tTG) in human serum or plasma. This product is intended for professional in vitro diagnostic use only.

Autoantibodies against tissue transglutaminase (tTG) during a gluten containing diet are the most obvious serologic feature of coeliac disease (CD). Determination of serum levels of IgA against tTG is the first choice in suspected CD. In subjects with either primary or secondary humoral IgA deficiency, at least one additional test measuring IgG class CD-specific antibodies is recommended. The clinical relevance of a positive anti-tTG result should be confirmed by histology of the small intestinal mucosa.

SYMBOLS USED ON LABELS

[17.45]			
IVD	In vitro diagnostic medical device	MICROPLATE	Microplate
***	Manufacturer	CALIBRATOR A	Calibrator
_	Manufacturer	CALIBRATOR B	Calibrator
REF	Catalogue number	CALIBRATOR C	Calibrator
$\overline{\Sigma}$	Sufficient for determinations	CALIBRATOR D	Calibrator
LOT	Batch code	CALIBRATOR E	Calibrator
_	Batch code	CALIBRATOR F	Calibrator
	Use by	CONTROL +	Control positive
X	Temperature limitation	CONTROL -	Control negative
类	Keep away from sunlight		
-		DILUENT	Sample Buffer P
(8)	Do not reuse	CONJUGATE	Enzyme Conjugate
M	Date of manufacture		
Ċ€	CE marked according to 98/79/EC	ТМВ	TMB Substrate
	, and the second	STOP	Stop solution
(i)	Consult electronic Instructions For Use	WASH	Wash Buffer
540A 5	Electronic Instruction For Use: version	RTU	Ready to use
		50 x	50 x concentrate

PRINCIPLE OF THE TEST

Human recombinant tissue transglutaminase is bound to microwells.

The determination is based on an indirect enzyme linked immune reaction with the following steps:

Specific antibodies in the patient sample bind to the antigen coated on the surface of the reaction wells. After incubation, a washing step removes unbound and unspecifically bound serum or plasma components. Subesquently added enzyme conjugate binds to the immobilized antibody-antigen-complexes. After incubation, a second washing step removes unbound enzyme conjugate. After addition of substrate solution the bound enzyme conjugate hydrolyses the substrate forming a blue coloured product. Addition of an acid stopps the reaction generating a yellow end-product. The intensity of the yellow color

correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 450 nm.

WARNINGS AND PRECAUTIONS

- · All reagents of this kit are intended for professional in vitro diagnostic use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- · Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
- Stop solution contains acid, classifiaction is non-hazardous. Avoid contact with skin.
- Control, sample buffer and wash buffer contain sodium azide 0.09% as preservative. This concentration is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.

During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:

- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove
 contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin,
 wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running
 water for at least 10 minutes. Get medical attention if necessary.
- Personal precautions, protective equipment and emergency procedures:

Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.

- Exposure controls / personal protection: Wear protective gloves of nitril rubber or natural latex.
 Wear protective glasses. Used according to intended use no dangerous reactions known.
- · Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
- · For disposal of laboratory waste the national or regional legislation has to be observed.

Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

CONTENTS OF THE KIT

ORG 540A	₹ 96	Sufficient for 96 determinations
MICROPLATE	1	One divisible microplate consisting of 12 modules of 8 wells each. Ready to use. Product code on module: <i>tTG</i>
CALIBRATOR A	1x 1.5 ml	Calibrator A 0 U/ml, containing serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR B	1x 1.5 ml	Calibrator B 5 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR C	1x 1.5 ml	Calibrator C 10 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR D	1x 1.5 ml	Calibrator D 25 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR E	1x 1.5 ml	Calibrator E 75 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR F	1x 1.5 ml	Calibrator F 200 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CONTROL +	1x 1.5 ml	Control positive, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.
CONTROL -	1x 1.5 ml	Control negative, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.
DILUENT	20 ml	Sample Buffer P, containing PBS, BSA, detergent, preservative sodium azide 0.09% , yellow, concentrate (5 x).
CONJUGATE	15 ml	Enzyme Conjugate; light red, containing anti-human IgA antibodies, HRP labelled; PBS, BSA, detergent, preservative PROCLIN 0.05%. Ready to use.
ТМВ	15 ml	TMB Substrate; containing 3,3', 5,5'- Tetramethylbenzidin, colorless. Ready to use.
STOP	15 ml	Stop solution; contains acid. Ready to use.
WASH	20 ml	Wash Buffer, containing Tris, detergent, preservative sodium azide 0.09%; 50 x conc.

MATERIALS REQUIRED

- · Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
- · Data reduction software
- Multi-channel dispenser or repeatable pipette for 100 μl
- · Vortex mixer
- Pipettes for 10 μl, 100 μl and 1000 μl
- · Laboratory timing device
- · Distilled or deionised water
- · Measuring cylinder for 1000 ml and 100 ml
- · Plastic container for storage of the wash solution

This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system. Detailed information is provided upon request.

SPECIMEN COLLECTION, STORAGE AND HANDLING

- Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- · Testing of heat-inactivated sera is not recommended.

STORAGE AND STABILITY

- · Store test kit at 2-8°C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store microplate sealed and dessicated in the clip bag provided.
- Shelf life of the unopended test kit is 18 months from day of production.
 Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash Buffer and Sample Buffer are stable for at least 30 days when stored at 2-8°C.
 We recommend consumption on the same day.

PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots and products.
- All materials must be at room temperature (20-28°C) prior to use.
- · Prepare all reagents and samples. Once started, performe the test without interruption.
- Double determinations may be done. By this means pipetting errors may become obvious.
- · Perform the assay steps only in the order indicated.
- · Always use fresh sample dilutions.
- · Pipette all reagents and samples into the bottom of the wells.
- · To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
- · Wash microwells thoroughly and remove the last droplets of wash buffer.
- · All incubation steps must be accurately timed.
- Do not re-use microplate wells.

PREPARATION OF REAGENTS

WASH

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

DILUENT

Sample Buffer P: Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 ml.

Preparation of samples

Dilute patient samples 1:100 before the assay: Put 990 µl of prediluted sample buffer in a polystyrene tube and add 10 µl of sample. Mix well. Note: Calibrators / Controls are ready to use and need not be diluted.

TEST PROCEDURE

Prepare enough microplate modules for all calibrators / controls and patient samples.

1. Pipette 100 ul of calibrators, controls and prediluted patient samples into the wells.

Incubate for 30 minutes at room temperature (20-28 °C).

Discard the contents of the microwells and wash 3 times with 300 ul of wash solution.

2. Dispense 100 µl of enzyme conjugate into each well.

Incubate for 15 minutes at room temperature.

Discard the contents of the microwells and wash 3 times with 300 µl of wash solution.

3. Dispense 100 µl of TMB substrate solution into each well.

Incubate for 15 minutes at room temperature

4. Add 100 ul of stop solution to each well of the modules

Incubate for 5 minutes at room temperature.

Read the optical density at 450 nm (reference 600-690nm) and calculate the results.

The developed colour is stable for at least 30 minutes. Read during this time.

Example for a pipetting scheme:

	1	2	3	4	5	6	7	8	9	10	11	12
Α	Α	P1										
В	В	P2										
С	С	P3										
D	D											
Ε	Е											
F	F											
G	C+											
Н	C-											

P1, ... patient sample A-F calibrators C+, C- controls

VALIDATION

Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit.

If these quality control criteria are not met the assay run is invalid and should be repeated.

CALCULATION OF RESULTS

For quantitative results plot the optical density of each calibrator versus the calibrator concentration to create a calibration curve. The concentration of patient samples may then be estimated from the calibration curve by interpolation.

Using data reduction software a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

PERFORMANCE CHARACTERISTICS

Calibration

This assay system is calibrated in relative arbitrary units, since no international reference preparation is available for this assay.

Measuring range

The calculation range of this ELISA assay is 0 - 200 U/ml

Expected values

In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay: Cut-off 10 U/ml

Interpretation of results

Negative: < 10 U/ml Positive: ≥ 10 U/ml

Linearity

Patient samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay and the upper / lower end of linearity. Activity for each dilution was calculated from the calibration curve using a 4-Parameter-Fit with lin-log coordinates.

Sample	Dilution	Observed	Expected	O/E
		U/ml	U/ml	[%]
1	1:100	<mark>196.9</mark>	196.9	100
	1:200	103.9	98.5	105
	1:400	49.0	49.2	100
	1:800	25.2	24.6	102
	1:1600	11.3	12.3	92
2	1:100	199.3	199.3	100
	1:200	100.8	99.7	101
	1:400	49.8	49.8	100
	1:800	25.8	24.9	104
	1:1600	<mark>11.7</mark>	12.5	94

Limit of detection

Functional sensitivity was determined to be: 1 U/ml

Reproducibility

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 8 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

Intra-Assay					
Sample	Mean				
	U/ml	CV %			
1	0.9	10.4			
2	47.1	4.4			
3	112.8	8.7			


Inter-Assay					
Sample Mean					
U/ml	CV %				
1.3	10.6				
19.4	13.7				
108.5	11.1				
	Mean U/ml 1.3 19.4				

Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparine). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

Study results

Study population	<u>n</u>	<u>n Pos</u>	<u>%</u>
Coeliac disease	35	35	100.0
Normal human sera	90	2	2.2



Sensitivity: 100.0 % Specificity: 97.8 % Overall agreement: 98.4 %

LIMITATIONS OF THE PROCEDURE

This assay is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated concerning the entire clinical picture of the patient. Also every decision for therapy should be taken individually.

The above pathological and normal reference ranges for antibodies in patient samples should be regarded as recommendations only. Each laboratory should establishe its own ranges according to ISO 15189 or other applicable laboratory guidelines.

REFERENCES

- Alessio M, Tonutti E, Brusca I, Radice A, Licini L, Sonzogni A, Florena A, Schiaffino E, Marus W, Sulfaro S, Villalta D: Correlation between IgA tissue transglutaminase antibody ratio and histological finding in celiac disease: A multicentre study. J Pediatr. Gastroenterol. Nutr. 2011.
- Cummins AG, Roberts-Thomson IC: Prevalence of celiac disease in the Asia-Pacific region. J Gastroenterol. Hepatol. 2009, 24:1347-1351.
- Giersiepen K, Lelgemann M, Stuhldreher N, Ronfani L, Husby S, Koletzko S, Korponay-Szabo IR: Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. J Pediatr. Gastroenterol. Nutr. 2012, 54:229-241.
- 4. Green PH, Cellier C: Celiac disease. N. Engl. J Med. 2007, 357:1731-1743.
- Gupta R, Reddy DN, Makharia GK, Sood A, Ramakrishna BS, Yachha SK, Thapa BR, Banerjee R, Anuradha S, Dutta U, Puri AS, Jain AK, Mulder CJ, Kumar A, Boindala S: Indian task force for celiac disease: current status. World J Gastroenterol. 2009. 15:6028-6033.
- Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D, Catassi C, Lelgeman M, Maki M, Ribes-Koninckx C, Ventura A, Zimmer KP: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr. Gastroenterol. Nutr. 2012, 54:136-160.
- Mahadov S, Green PH: Celiac disease: a challenge for all physicians. Gastroenterol. Hepatol.(N Y) 2011, 7:554
- 8. Marietta EV, Rashtak S, Murray JA: Correlation analysis of celiac sprue tissue transglutaminase and deamidated gliadin IgG/IgA. World J Gastroenterol. 2009, 15:845-848.
- 9. Murray JA: Serodiagnosis of celiac disease. Clin. Lab. Med. 1997, 17:445-464.
- 10. Rubio-Tapia A, Murray JA: Celiac disease. Curr. Opin. Gastroenterol. 2010, 26:116-122.
- Telega G, Bennet TR, Werlin S: Emerging new clinical patterns in the presentation of celiac disease. Arch. Pediatr. Adolesc. Med 2008, 162:164-168.
- 12. Tjon JM, van BJ, Koning F: Celiac disease: how complicated can it get? Immunogenetics 2010, 62:641-651.
- 13. van der Windt DA, Jellema P, Mulder CJ, Kneepkens CM, van der Horst HE: Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA 2010, 303:1738-1746.
- 14. Villalta D, Tonutti E, Prause C, Koletzko S, Uhlig HH, Vermeersch P, Bossuyt X, Stern M, Laass MW, Ellis JH, Ciclitira PJ, Richter T, Daehnrich C, Schlumberger W, Mothes T: IgG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IgA deficiency. Clin. Chem. 2010, 56:464-468.

Notice to the user (European Union):

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the EU Member State in which the user and/or the patient is established.

Change Control

Former version: ORG 540A IFU EN QM113174 2018-01-02 4 Reason for revision: Definition of symbols used and symbols updated

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

100

ORGENTEC Diagnostika GmbH

Carl-Zeiss-Straße 49-51 55129 Mainz - Germany

Phone: +49 (0) 61 31 / 92 58-0 Fax: +49 (0) 61 31 / 92 58-58

Internet: www.orgentec.com



www.orgentec.com







REF ORG 540G Anti-Tissue-Transglutaminase IgG

INTENDED PURPOSE

Anti-Tissue-Transglutaminase IgG is an ELISA test system for the quantitative measurement of IgG class autoantibodies to tissue-transglutaminase (tTG) in human serum or plasma. This product is intended for professional in vitro diagnostic use only.

Autoantibodies against tissue transglutaminase (tTG) during a gluten containing diet are the most obvious serologic feature of coeliac disease (CD). Determination of serum levels of IgA against tTG is the first choice in suspected CD. In subjects with either primary or secondary humoral IgA deficiency, at least one additional test measuring IgG class CD-specific antibodies is recommended. The clinical relevance of a positive anti-tTG result should be confirmed by histology of the small intestinal mucosa.

SYMBOLS USED ON LABELS

IVD	In vitro diagnostic medical device	MICROPLATE	Microplate
	Manufacturer	CALIBRATOR A	Calibrator
	Manufacture:	CALIBRATOR B	Calibrator
REF	Catalogue number	CALIBRATOR C	Calibrator
Σ	Sufficient for determinations	CALIBRATOR D	Calibrator
LOT	Batch code	CALIBRATOR E	Calibrator
	Daton code	CALIBRATOR F	Calibrator
$\geq \leq$	Use by	CONTROL +	Control positive
X	Temperature limitation	CONTROL -	Control negative
类	Keep away from sunlight		
-	D	DILUENT	Sample Buffer P
(2)	Do not reuse	CONJUGATE	Enzyme Conjugate
\sim	Date of manufacture		
Ċ€	CE marked according to 98/79/EC	ТМВ	TMB Substrate
	-	STOP	Stop solution
(i	Consult electronic Instructions For Use	WASH	Wash Buffer
540G 5	Electronic Instruction For Use: version	RTU	Ready to use
		50 x	50 x concentrate

PRINCIPLE OF THE TEST

Human recombinant tissue transglutaminase is bound to microwells.

The determination is based on an indirect enzyme linked immune reaction with the following steps:

Specific antibodies in the patient sample bind to the antigen coated on the surface of the reaction wells. After incubation, a washing step removes unbound and unspecifically bound serum or plasma components. Subesquently added enzyme conjugate binds to the immobilized antibody-antigen-complexes. After incubation, a second washing step removes unbound enzyme conjugate. After addition of substrate solution the bound enzyme conjugate hydrolyses the substrate forming a blue coloured product. Addition of an acid stopps the reaction generating a yellow end-product. The intensity of the yellow color

correlates with the concentration of the antibody-antigen-complex and can be measured photometrically at 450 nm.

WARNINGS AND PRECAUTIONS

- All reagents of this kit are intended for professional in vitro diagnostic use only.
- Components containing human serum were tested and found negative for HBsAg, HCV, HIV1 and HIV2 by FDA approved methods. No test can guarantee the absence of HBsAg, HCV, HIV1 or HIV2, and so all human serum based reagents in this kit must be handled as though capable of transmitting infection.
- · Bovine serum albumin (BSA) used in components has been tested for BSE and found negative.
- Avoid contact with the substrate TMB (3,3',5,5'-Tetramethyl-benzidine).
- Stop solution contains acid, classifiaction is non-hazardous. Avoid contact with skin.
- Control, sample buffer and wash buffer contain sodium azide 0.09% as preservative. This concentration
 is classified as non-hazardous.
- Enzyme conjugate contains ProClin 300 0.05% as preservative. This concentration is classified as non-hazardous.

During handling of all reagents, controls and serum samples observe the existing regulations for laboratory safety regulations and good laboratory practice:

- First aid measures: In case of skin contact, immediately wash thoroughly with water and soap. Remove
 contaminated clothing and shoes and wash before reuse. If system fluid comes into contact with skin,
 wash thoroughly with water. After contact with the eyes carefully rinse the opened eye with running
 water for at least 10 minutes. Get medical attention if necessary.
- Personal precautions, protective equipment and emergency procedures:

Observe laboratory safety regulations. Avoid contact with skin and eyes. Do not swallow. Do not pipette by mouth. Do not eat, drink, smoke or apply makeup in areas where specimens or kit reagents are handled. When spilled, absorb with an inert material and put the spilled material in an appropriate waste disposal.

- Exposure controls / personal protection: Wear protective gloves of nitril rubber or natural latex.
 Wear protective glasses. Used according to intended use no dangerous reactions known.
- · Conditions to avoid: Since substrate solution is light-sensitive. Store in the dark.
- · For disposal of laboratory waste the national or regional legislation has to be observed.

Observe the guidelines for performing quality control in medical laboratories by assaying control sera.

CONTENTS OF THE KIT

ORG 540G	₹ 96	Sufficient for 96 determinations
MICROPLATE	1	One divisible microplate consisting of 12 modules of 8 wells each. Ready to use. Product code on module: <i>tTG</i>
CALIBRATOR A	1x 1.5 ml	Calibrator A 0 U/ml, containing serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR B	1x 1.5 ml	Calibrator B 5 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR C	1x 1.5 ml	Calibrator C 10 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR D	1x 1.5 ml	Calibrator D 25 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR E	1x 1.5 ml	Calibrator E 75 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, NaN3 0.09%), yellow. Ready to use.
CALIBRATOR F	1x 1.5 ml	Calibrator F 200 U/ml, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use.
CONTROL +	1x 1.5 ml	Control positive, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.
CONTROL -	1x 1.5 ml	Control negative, containing tTG antibodies in a serum/buffer matrix (PBS, BSA, detergent, NaN3 0.09%), yellow. Ready to use. The concentration is specified on the certificate of analysis.
DILUENT	20 ml	Sample Buffer P, containing PBS, BSA, detergent, preservative sodium azide 0.09% , yellow, concentrate (5 x) .
CONJUGATE	15 ml	Enzyme Conjugate containing anti-human IgG antibodies, HRP labelled; PBS, BSA, detergent, preservative PROCLIN 0.05%, light red. Ready to use.
ТМВ	15 ml	TMB Substrate; containing 3,3', 5,5'- Tetramethylbenzidin, colorless. Ready to use.
STOP	15 ml	Stop solution; contains acid. Ready to use.
WASH	20 ml	Wash Buffer, containing Tris, detergent, preservative sodium azide 0.09%; 50 x conc.

MATERIALS REQUIRED

- · Microplate reader capable of endpoint measurements at 450 nm; optional: reference filter at 620 nm
- Data reduction software
- Multi-channel dispenser or repeatable pipette for 100 μl
- Vortex mixer
- Pipettes for 10 μl, 100 μl and 1000 μl
- · Laboratory timing device
- · Distilled or deionised water
- Measuring cylinder for 1000 ml and 100 ml
- Plastic container for storage of the wash solution

This ELISA assay is suitable for use on open automated ELISA processors. Each assay has to be validated on the respective automated system. Detailed information is provided upon request.

SPECIMEN COLLECTION, STORAGE AND HANDLING

- · Collect whole blood specimens using acceptable medical techniques to avoid hemolysis.
- Allow blood to clot and separate the serum or plasma by centrifugation.
- Test serum should be clear and non-hemolyzed. Contamination by hemolysis or lipemia should be avoided, but does not interfere with this assay.
- Specimens may be refrigerated at 2-8°C for up to five days or stored at -20°C up to six months.
- Avoid repetitive freezing and thawing of serum or plasma samples. This may result in variable loss of antibody activity.
- · Testing of heat-inactivated sera is not recommended.

STORAGE AND STABILITY

- · Store test kit at 2-8°C in the dark.
- Do not expose reagents to heat, sun, or strong light during storage and usage.
- Store microplate sealed and dessicated in the clip bag provided.
- Shelf life of the unopended test kit is 18 months from day of production.
 Unopened reagents are stable until expiration of the kit. See labels for individual batch.
- Diluted Wash Buffer and Sample Buffer are stable for at least 30 days when stored at 2-8°C.
 We recommend consumption on the same day.

PROCEDURAL NOTES

- Do not use kit components beyond their expiration dates.
- Do not interchange kit components from different lots and products.
- All materials must be at room temperature (20-28°C) prior to use.
- · Prepare all reagents and samples. Once started, performe the test without interruption.
- Double determinations may be done. By this means pipetting errors may become obvious.
- · Perform the assay steps only in the order indicated.
- · Always use fresh sample dilutions.
- · Pipette all reagents and samples into the bottom of the wells.
- To avoid carryover or contamination, change the pipette tip between samples and different kit controls.
- · Wash microwells thoroughly and remove the last droplets of wash buffer.
- · All incubation steps must be accurately timed.
- Do not re-use microplate wells.

PREPARATION OF REAGENTS

WASH

Dilute the contents of one vial of the buffered wash solution concentrate (50x) with distilled or deionised water to a final volume of 1000 ml prior to use.

DILUENT

Sample Buffer P: Prior to use dilute the contents (20 ml) of one vial of sample buffer 5x concentrate with distilled or deionised water to a final volume of 100 ml.

Preparation of samples

Dilute patient samples 1:100 before the assay: Put 990 µl of prediluted sample buffer in a polystyrene tube and add 10 µl of sample. Mix well. Note: Calibrators / Controls are ready to use and need not be diluted.

TEST PROCEDURE

Prepare enough microplate modules for all calibrators / controls and patient samples.

1. Pipette 100 ul of calibrators, controls and prediluted patient samples into the wells.

Incubate for 30 minutes at room temperature (20-28 °C).

Discard the contents of the microwells and wash 3 times with 300 µl of wash solution.

2. Dispense 100 µl of enzyme conjugate into each well.

Incubate for 15 minutes at room temperature.

Discard the contents of the microwells and wash 3 times with 300 µl of wash solution.

3. Dispense 100 µl of TMB substrate solution into each well.

Incubate for 15 minutes at room temperature

4. Add 100 ul of stop solution to each well of the modules

Incubate for 5 minutes at room temperature.

Read the optical density at 450 nm (reference 600-690nm) and calculate the results.

The developed colour is stable for at least 30 minutes. Read during this time.

Example for a pipetting scheme:

	1	2	3	4	5	6	7	8	9	10	11	12
Α	Α	P1										
В	В	P2										
С	С	P3										
D	D											
Е	Е											
F	F											
G	C+											
Н	C-											

P1, ... patient sample A-F calibrators C+, C- controls

VALIDATION

Test results are valid if the optical densities at 450 nm for calibrators / controls and the results for controls comply with the reference ranges indicated on the Certificate of Analysis enclosed in each test kit.

If these quality control criteria are not met the assay run is invalid and should be repeated.

CALCULATION OF RESULTS

For quantitative results plot the optical density of each calibrator versus the calibrator concentration to create a calibration curve. The concentration of patient samples may then be estimated from the calibration curve by interpolation.

Using data reduction software a 4-Parameter-Fit with lin-log coordinates for optical density and concentration is the data reduction method of choice.

PERFORMANCE CHARACTERISTICS

Calibration

This assay system is calibrated in relative arbitrary units, since no international reference preparation is available for this assay.

Measuring range

The calculation range of this ELISA assay is 0 - 200 U/ml

Expected values

In a normal range study with samples from healthy blood donors the following ranges have been established with this ELISA assay: Cut-off 10 U/ml

Interpretation of results

Negative: < 10 U/ml Positive: ≥ 10 U/ml

Linearity

Patient samples containing high levels of specific antibody were serially diluted in sample buffer to demonstrate the dynamic range of the assay and the upper / lower end of linearity. Activity for each dilution was calculated from the calibration curve using a 4-Parameter-Fit with lin-log coordinates.

Sample	Dilution	Observed	Expected	O/E
		U/ml	U/ml	[%]
1	1:100	188.0	188.0	100
	1:200	101.7	94.0	108
	1:400	48.4	47.0	103
	1:800	24.1	23.5	103
	1:1600	<mark>10.9</mark>	11.8	93
2	1:100	<mark>196.0</mark>	196.0	100
•	1:200	97.2	98.0	99
•	1:400	49.4	49.0	101
•	1:800	24.8	24.5	101
	1:1600	11.9	12.3	97

Limit of detection

Functional sensitivity was determined to be: 1 U/ml

Reproducibility

Intra-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 24 determinations in a single run. Results for precision-within-assay are shown in the table below.

Inter-assay precision: Coefficient of variation (CV) was calculated for each of three samples from the results of 8 determinations in 5 different runs. Results for run-to-run precision are shown in the table below.

Intra-Assay					
Sample	Mean				
	U/ml	CV %			
1	4.2	6.5			
2	20.7	6.7			
3	63.7	6.1			


Inter-Assay			
Sample	Mean		
	U/ml	CV %	
1	4.5	10.9	
2	22.4	9.2	
3	74.0	8.8	

Interfering substances

No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic (up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containing sera or plasma. Nor have any interfering effects been observed with the use of anticoagulants (Citrate, EDTA, Heparine). However for practical reasons it is recommended that grossly hemolyzed or lipemic samples should be avoided.

Study results

Study population	<u>n</u>	n Pos	<u>%</u>
Coeliac disease	35	23	65.7
Coeliac disease (IgA deficient)	8	8	100.0
Normal human sera	90	0	0.0



Sensitivity: 72.1 % Specificity: 100.0 %

Overall agreement: 91.0 %

LIMITATIONS OF THE PROCEDURE

This assay is a diagnostic aid. A definite clinical diagnosis should not be based on the results of a single test, but should be made by the physician after all clinical and laboratory findings have been evaluated concerning the entire clinical picture of the patient. Also every decision for therapy should be taken individually.

The above pathological and normal reference ranges for antibodies in patient samples should be regarded as recommendations only. Each laboratory should establishe its own ranges according to ISO 15189 or other applicable laboratory guidelines.


REFERENCES

- 1. Alessio M, Tonutti E, Brusca I, Radice A, Licini L, Sonzogni A, Florena A, Schiaffino E, Marus W, Sulfaro S, Villalta D: Correlation between IgA tissue transglutaminase antibody ratio and histological finding in celiac disease: A multicentre study. J Pediatr. Gastroenterol. Nutr. 2011.
- 2. Cummins AG, Roberts-Thomson IC: Prevalence of celiac disease in the Asia-Pacific region. J Gastroenterol. Hepatol. 2009, 24:1347-1351.
- 3. Giersiepen K. Lelgemann M. Stuhldreher N. Ronfani L. Husby S. Koletzko S. Korponay-Szabo IR: Accuracy of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. J Pediatr. Gastroenterol, Nutr. 2012, 54:229-241.
- 4. Green PH, Cellier C: Celiac disease. N. Engl. J Med. 2007, 357:1731-1743.
- 5. Gupta R, Reddy DN, Makharia GK, Sood A, Ramakrishna BS, Yachha SK, Thapa BR, Banerjee R, Anuradha S, Dutta U, Puri AS, Jain AK, Mulder CJ, Kumar A, Boindala S: Indian task force for celiac disease: current status. World J Gastroenterol, 2009, 15:6028-6033.
- 6. Husby S, Koletzko S, Korponay-Szabo IR, Mearin ML, Phillips A, Shamir R, Troncone R, Giersiepen K, Branski D. Catassi C. Lelgeman M. Maki M. Ribes-Koninckx C. Ventura A. Zimmer KP: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr. Gastroenterol, Nutr. 2012, 54:136-160.
- 7. Mahadov S. Green PH: Celiac disease: a challenge for all physicians, Gastroenterol, Hepatol (N Y) 2011, 7:554 -556
- 8. Marietta EV, Rashtak S, Murray JA: Correlation analysis of celiac sprue tissue transglutaminase and deamidated gliadin IgG/IgA. World J Gastroenterol. 2009, 15:845-848.
- 9. Murray JA: Serodiagnosis of celiac disease, Clin. Lab. Med. 1997, 17:445-464.
- 10. Rubio-Tapia A. Murray JA: Celiac disease, Curr. Opin. Gastroenterol. 2010, 26:116-122.
- 11. Telega G. Bennet TR. Werlin S: Emerging new clinical patterns in the presentation of celiac disease. Arch. Pediatr. Adolesc. Med 2008. 162:164-168.
- 12. Tion JM, van BJ, Koning F; Celiac disease; how complicated can it get? Immunogenetics 2010, 62:641-651,
- 13. van der Windt DA, Jellema P, Mulder CJ, Kneepkens CM, van der Horst HE: Diagnostic testing for celiac disease among patients with abdominal symptoms: a systematic review. JAMA 2010, 303:1738-1746.
- 14. Villalta D, Tonutti E, Prause C, Koletzko S, Uhlig HH, Vermeersch P, Bossuyt X, Stern M, Laass MW, Ellis JH, Ciclitira PJ, Richter T, Daehnrich C, Schlumberger W, Mothes T: IqG antibodies against deamidated gliadin peptides for diagnosis of celiac disease in patients with IqA deficiency, Clin. Chem. 2010, 56:464-468.

Notice to the user (European Union):

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the EU Member State in which the user and/or the patient is established .

Former version: ORG 540G IFU EN QM113175 2018-01-02 4 Reason for revision: Definition of symbols used and symbols updated





EG Konformitätserklärung

EC Declaration of Conformity

ORGENTEC Diagnostika GmbH Carl-Zeiss-Straße 49-51, 55129 Mainz, GERMANY

Wir erklären in eigener Verantwortung, dass das ORGENTEC Produkt We declare in our sole responsibility that the ORGENTEC product

ORG 540A Anti-Tissue-Transglutaminase IgA

zur quantitativen in-vitro-Bestimmung bestimmt ist und entsprechend Art. 9 Abs. Satz 1 der Europäischen Richtlinie 98/79/EG als "Sonstige Produkte" (non-A, non-B, keine Selbstanwendung) klassifiziert ist.

as intended for use in quantitative in vitro determination is classified as "Other Devices" (non-A, non-B, no self-testing device) according to article 9 paragraph 1 sentence 1 of the European directive 98/79/EC.

Das Produkt stimmt mit den Grundlegenden Anforderungen und allen zutreffenden Bestimmungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über in-vitro-Diagnostika überein. Die Konformität zur Richtlinie wurde durch ein Konformitätsbewertungsverfahren nach Anhang III der Richtlinie festgestellt.

This product is conform with the essential requirements and meet the appropriate provisions of the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Conformity was proved by a conformity assessment procedure referred to in annex III of the directive.

Liste angewendeter Normen:

List of standards applied for CE marking: EN ISO 13485, EN ISO 14971, EN ISO 18113, EN ISO 15223, EN ISO 23640, EN 13612.

Mainz, 2021-02-05

René Betz Head of Regulatory Affairs

Gültig ab / Valid from 2021-02-05 bis / until 2024-02-28

Notification pursuant to §25 Abs. 3 Nr. 3 Medical Devices Act, MPG

Type: Reagent

EDMS 12-10-90-21-00

GMDN 55223

ORG 540A_CE declaration of conformity_QM120359_2021-02-05_8

F4.01B Declaration of conformity

ORGENTEC

EG Konformitätserklärung

EC Declaration of Conformity

ORGENTEC Diagnostika GmbH Carl-Zeiss-Straße 49-51, 55129 Mainz, GERMANY

Wir erklären in eigener Verantwortung, dass das ORGENTEC Produkt We declare in our sole responsibility that the ORGENTEC product

ORG 540G Anti-Tissue-Transglutaminase IgG

zur quantitativen in-vitro-Bestimmung bestimmt ist und entsprechend Art. 9 Abs. Satz 1 der Europäischen Richtlinie 98/79/EG als "Sonstige Produkte" (non-A, non-B, keine Selbstanwendung) klassifiziert ist.

as intended for use in quantitative in vitro determination is classified as "Other Devices" (non-A, non-B, no self-testing device) according to article 9 paragraph 1 sentence 1 of the European directive 98/79/EC.

Das Produkt stimmt mit den Grundlegenden Anforderungen und allen zutreffenden Bestimmungen der Richtlinie 98/79/EG des Europäischen Parlaments und des Rates vom 27. Oktober 1998 über in-vitro-Diagnostika überein. Die Konformität zur Richtlinie wurde durch ein Konformitätsbewertungsverfahren nach Anhang III der Richtlinie festgestellt.

This product is conform with the essential requirements and meet the appropriate provisions of the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. Conformity was proved by a conformity assessment procedure referred to in annex III of the directive.

Liste angewendeter Normen:

List of standards applied for CE marking: EN ISO 13485, EN ISO 14971, EN ISO 18113, EN ISO 15223, EN ISO 23640, EN 13612.

Mainz, 2021-02-05

René Betz

Head of Regulatory Affairs

Gültig ab / Valid from 2021-02-05 bis / until 2024-02-28

Notification pursuant to §25 Abs. 3 Nr. 3 Medical Devices Act, MPG

Type: Reagent

EDMS 12-10-90-21-00

GMDN 55223

ORG 540G CE declaration of conformity QM120360 2021-02-05 8

F4.01B Declaration of conformity